Cleared Traditional

K190593 - Zio XT ECG Monitoring System, Zio AT ECG Monitoring System

K190593 is an FDA 510(k) clearance for Zio XT ECG Monitoring System, manufactured by iRhythm Technologies, Inc.. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 169-day FDA review.

K190593 · iRhythm Technologies, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2019
Decision
169d
Days
Class 2
Risk

K190593 is an FDA 510(k) clearance for the Zio XT ECG Monitoring System, Zio AT ECG Monitoring System. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by iRhythm Technologies, Inc. (San Francisco, US). The FDA issued a Cleared decision on August 23, 2019 after a review of 169 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all iRhythm Technologies, Inc. devices

FDA 510(k) Submission Details - K190593

510(k) Number K190593 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 07, 2019
Decision Date August 23, 2019
Days to Decision 169 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
44d slower than avg
Panel avg: 125d · This submission: 169d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 359
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K190593.
Rhythmia HDxTM Mapping System
K192438 · Boston Scientific Corporation · Nov 2019
AcQMap High Resolution Imaging and Mapping System
K191392 · Acutus Medical, Inc. · Sep 2019
HemoSphere Advanced Monitor, HemoSphere Tissue Oximetry Module
K190205 · Edwards Lifesciences, LLC · Aug 2019
CARTO 3 EP Navigation System, Version 7.1 and Accessories
K191660 · Biosense Webster, Inc. · Jul 2019
iLab Polaris Multi-Modality Guidance System
K191008 · Boston Scientific Corporation · Jul 2019
Intra-Operative Positioning System
K190106 · Centerline Biomedical, Inc. · Jun 2019